Imidazoline receptor agonists: more than blood pressure reduction?
The review contains original data and international studies’ results demonstrating that selective I1 imidazoline receptor agonists, and, in particular, Albarel®, a new sympatholytic agent, provide not only adequate and longterm blood pressure control, but also other beneficial metabolic and vascular...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2006-04-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342059232624640 |
|---|---|
| author | D. V. Nebieridze S. V. Nedogoda |
| author_facet | D. V. Nebieridze S. V. Nedogoda |
| author_sort | D. V. Nebieridze |
| collection | DOAJ |
| description | The review contains original data and international studies’ results demonstrating that selective I1 imidazoline receptor agonists, and, in particular, Albarel®, a new sympatholytic agent, provide not only adequate and longterm blood pressure control, but also other beneficial metabolic and vascular effects. Most important ones are insulin resistance reduction, improvement of endothelial function and elasticity in middle-sized and large vessels. In Russian guidelines on arterial hypertension diagnostics and treatment, this medication class is recommended in patients with metabolic disturbances. Nevertheless, in real-world clinical practice, the indications might be widened, including sympathetic hyperactivity in post-menopause women, patients with insulin resistance, chronic obstructive pulmonary disease, and bronchial asthma. |
| format | Article |
| id | doaj-art-5283bf1629764e7cbc0edde03f9d3c4c |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2006-04-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-5283bf1629764e7cbc0edde03f9d3c4c2025-08-20T03:43:30Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252006-04-0152112117881Imidazoline receptor agonists: more than blood pressure reduction?D. V. Nebieridze0S. V. Nedogoda1State Research Center for Preventive Medicine, Russian Federal Agency of Health and Social Development. MoscowVolgograd State Medical Academy. VolgogradThe review contains original data and international studies’ results demonstrating that selective I1 imidazoline receptor agonists, and, in particular, Albarel®, a new sympatholytic agent, provide not only adequate and longterm blood pressure control, but also other beneficial metabolic and vascular effects. Most important ones are insulin resistance reduction, improvement of endothelial function and elasticity in middle-sized and large vessels. In Russian guidelines on arterial hypertension diagnostics and treatment, this medication class is recommended in patients with metabolic disturbances. Nevertheless, in real-world clinical practice, the indications might be widened, including sympathetic hyperactivity in post-menopause women, patients with insulin resistance, chronic obstructive pulmonary disease, and bronchial asthma.https://cardiovascular.elpub.ru/jour/article/view/1169i1 imidazoline receptor agonistsalbarel®metabolic effectsendothelial dysfunctionvascular elasticity |
| spellingShingle | D. V. Nebieridze S. V. Nedogoda Imidazoline receptor agonists: more than blood pressure reduction? Кардиоваскулярная терапия и профилактика i1 imidazoline receptor agonists albarel® metabolic effects endothelial dysfunction vascular elasticity |
| title | Imidazoline receptor agonists: more than blood pressure reduction? |
| title_full | Imidazoline receptor agonists: more than blood pressure reduction? |
| title_fullStr | Imidazoline receptor agonists: more than blood pressure reduction? |
| title_full_unstemmed | Imidazoline receptor agonists: more than blood pressure reduction? |
| title_short | Imidazoline receptor agonists: more than blood pressure reduction? |
| title_sort | imidazoline receptor agonists more than blood pressure reduction |
| topic | i1 imidazoline receptor agonists albarel® metabolic effects endothelial dysfunction vascular elasticity |
| url | https://cardiovascular.elpub.ru/jour/article/view/1169 |
| work_keys_str_mv | AT dvnebieridze imidazolinereceptoragonistsmorethanbloodpressurereduction AT svnedogoda imidazolinereceptoragonistsmorethanbloodpressurereduction |